Sliutz G, Tempfer C, Winkler S, Kohlberger P, Reinthaller A, Kainz C
Department of Gynaecology and Obstetrics, University of Vienna, Medical School, Austria.
Br J Cancer. 1995 Dec;72(6):1494-7. doi: 10.1038/bjc.1995.535.
The surface glycoprotein CD44 is widely distributed in different tissues. In contrast to healthy tissue, tumour samples show a more complex pattern of CD44 expression, indicating a loss of splice control. Beside cell-surface expression, the measurement of soluble CD44 in serum of cancer patients could be useful in early diagnosis and assessment of disease status. We evaluated the surface expression of CD44 isoforms in 22 ovarian cancer patients by means of immunohistochemistry. Additionally, we investigated 134 serological samples of these patients for the occurrence of CD44 isoform expression. For CD44 standard, CD44v5 and CF44v6 mean serum levels in patients with clinically detectable or non-detectable ovarian cancer were 422.4 +/- 143.8 ng ml-1 and 547.4 +/- 148.2 ng ml-1, 12.3 +/- 7.9 ng ml-1 and 21.9 +/- 12.2 ng ml-1 and 105.5 +/- 37.9 ng ml-1 and 144.9 +/- 50.9 ng ml-1 respectively (P-values not significant). CD44 surface proteins containing epitopes encoded by splice variants CD44v5, CD44v6 and CD44v7-8 were immunohistochemically detected in 9% (n = 2), 13% (n = 3) and 4% (n = 1) of the 22 tumour samples respectively. In the present study we showed that in ovarian cancer CD44 isoforms CD44v5 and CD44v6 are expressed in very low amounts by the tumours. In accordance with this, we found that the presence of tumour is not associated with higher serum levels of CD44standard, CD44v5 and CD44v6 in preoperative serum samples in ovarian cancer patients.
表面糖蛋白CD44广泛分布于不同组织中。与健康组织不同，肿瘤样本显示出更复杂的CD44表达模式，表明剪接控制丧失。除了细胞表面表达外，检测癌症患者血清中的可溶性CD44可能有助于早期诊断和疾病状态评估。我们通过免疫组织化学评估了22例卵巢癌患者中CD44亚型的表面表达。此外，我们研究了这些患者的134份血清样本中CD44亚型表达的情况。对于CD44标准品、CD44v5和CD44v6，临床可检测或不可检测卵巢癌患者的平均血清水平分别为422.4±143.8 ng/ml和547.4±148.2 ng/ml、12.3±7.9 ng/ml和21.9±12.2 ng/ml、105.5±37.9 ng/ml和144.9±50.9 ng/ml（P值无统计学意义）。在22个肿瘤样本中，分别有9%（n = 2）、13%（n = 3）和4%（n = 1）通过免疫组织化学检测到含有由剪接变体CD44v5、CD44v6和CD44v7 - 8编码表位的CD44表面蛋白。在本研究中，我们表明在卵巢癌中，肿瘤表达的CD44亚型CD44v5和CD44v6含量非常低。据此，我们发现卵巢癌患者术前血清样本中肿瘤的存在与CD44标准品、CD44v5和CD44v6的血清水平升高无关。
